Evidence map›Paper›PMID 42268527›Full record

ArticleJournal of applied genetics2026

Deciphering programmed cell death for gastric cancer prognosis: AKR1B1 as a key player.

Shan-Peng Liu, Xiaomin Li, Qin Liu, Shun Xie

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shan-Peng LiuDepartment of Thoracic Surgery, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Shanwei, Guangdong, China.
Xiaomin LiDepartment of Nutrition and Food Hygiene, College of Public Health, Key Laboratory of Precision Nutrition and Health, Ministry of Education, Harbin Medical University, Heilongjiang, 150081, China.
Qin LiuThe People's Hospital of Dazu, Chongqing / The Affiliated Dazu's Hospital of Chongqing Medical University, Dazu, 402360, China.
Shun XieDepartment of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China. xieshun_thoracic@163.com.ORCID http://orcid.org/0009-0008-1523-0972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) has poor survival due to late diagnosis, heterogeneity, and limited treatment options. Understanding cell death pathways is crucial for developing effective therapies. This study aimed to investigate the prognostic value of multiple Programmed cell death (PCD) in GC, identify key genes associated with PCD. Bioinformatics methods including Cox regression and machine learning algorithms identified key genes. Evaluation of key gene by immune infiltration, single-cell analysis, drug sensitivity. In vitro experiments using siRNA knockdown of hub gene in GC cell lines confirmed the findings. The study developed prognostic models for 12 PCD pathways, finding extrinsic apoptosis and immunogenic cell death were most predictive of patient survival. A comprehensive risk model was built integrating 22 hub genes across 12 PCD pathways. Machine learning identified Aldo-keto reductase 1 member B1 (AKR1B1) as a key prognostic gene, which was validated to promote proliferation and migration in gastric cancer cells. AKR1B1 expression correlated with immune infiltration and drug sensitivity, suggesting a role in shaping the tumor microenvironment. This study reveals complex cell death mechanisms in GC, identifying key genes for targeted therapies. Further research on AKR1B1 and other genes holds promise for novel therapeutic strategies to combat GC and improve outcomes.

Indexed as

AKR1B1Machine learning, gastric carcinomaPCD

Identifiers

PMID42268527

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.